| Lung Cancer Treatments and Mutations | Lifetime | 266 | US 140 | 99.29 |
| Lung Cancer Research Studies | Lifetime | 305 | US 138 | 98.76 |
| Colorectal Cancer Treatments and Studies | Lifetime | 343 | US 162 | 98.93 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 619 | US 315 | 98.63 |
| Peptidase Inhibition and Analysis | Lifetime | 992 | US 439 | 96.98 |
| HER2/EGFR in Cancer Research | Lifetime | 850 | US 384 | 96.64 |
| Cancer therapeutics and mechanisms | Lifetime | 944 | US 460 | 95.67 |
| Advanced Breast Cancer Therapies | Lifetime | 537 | US 238 | 95.81 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 939 | US 497 | 93.63 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 11 | US 3 | 99.93 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 6 | US 1 | 99.89 |
| Lung Cancer Research Studies | 2021-2025 | 15 | US 4 | 99.76 |
| Cancer Genomics and Diagnostics | 2021-2025 | 95 | US 54 | 99.23 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 57 | US 18 | 99.18 |
| Cancer Research and Treatments | 2021-2025 | 20 | US 4 | 98.02 |
| Peptidase Inhibition and Analysis | 2021-2025 | 39 | US 10 | 99.06 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 178 | US 71 | 99.31 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 116 | US 25 | 98.75 |
| Cancer therapeutics and mechanisms | 2021-2025 | 21 | US 8 | 98.06 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 21 | US 14 | 95.78 |
| HER2/EGFR in Cancer Research | 2021-2025 | 89 | US 32 | 98.59 |
| CAR-T cell therapy research | 2021-2025 | 302 | US 171 | 97.94 |
| Advanced Breast Cancer Therapies | 2021-2025 | 108 | US 38 | 98.19 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 394 | US 132 | 97.00 |
| Immunotherapy and Immune Responses | 2021-2025 | 355 | US 124 | 95.47 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 267 | US 92 | 95.40 |
| Cancer Treatment and Pharmacology | 2021-2025 | 189 | US 62 | 96.32 |
| Genetic factors in colorectal cancer | 2021-2025 | 376 | US 137 | 93.18 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 204 | US 47 | 85.26 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 616 | US 153 | 89.52 |
| Melanoma and MAPK Pathways | 2021-2025 | 259 | US 84 | 87.81 |
| Cancer-related gene regulation | 2021-2025 | 968 | US 153 | 76.29 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 201 | US 105 | 73.80 |
| Phagocytosis and Immune Regulation | 2021-2025 | 641 | US 177 | 70.90 |
| Chromatin Remodeling and Cancer | 2021-2025 | 627 | US 255 | 62.71 |
| Chemical Reactions and Isotopes | 2021-2025 | 303 | US 42 | 64.10 |
| Mechanisms of cancer metastasis | 2021-2025 | 87 | US 19 | 50.44 |
